Non-alcoholic fatty liver disease: An emerging liver disease in Taiwan

Ching-Sheng Hsu\textsuperscript{a,b,c}, Jia-Horng Kao\textsuperscript{d,e,f,*}

\textsuperscript{a} Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei Branch, Taiwan
\textsuperscript{b} School of Medicine, Tzu Chi University, Hualien, Taiwan
\textsuperscript{c} Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
\textsuperscript{d} Department of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
\textsuperscript{e} Department of Medical Research, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
\textsuperscript{f} Hepatitis Research Center, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan

Received 25 December 2011; received in revised form 4 July 2012; accepted 4 July 2012

KEYWORDS
fatty liver; hepatitis B virus; hepatitis C virus; metabolic syndrome; NASH; Taiwan

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in Western countries, and has become increasingly recognized as a public health problem in Taiwan. Patients with non-alcoholic steatohepatitis, a more severe form of NAFLD, may progress to cirrhosis and its related complications, including hepatocellular carcinoma. Since NAFLD is highly linked to metabolic syndrome, such patients may have increased risks of complications related to both liver disease and metabolic syndrome. Therefore, if we fail to cope with this growing health problem, NAFLD may gradually replace viral hepatitis as the major etiology of liver disease in Taiwan.

Copyright © 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.

Abbreviations: ALT, alanine aminotransferase; APASL, Asian Pacific Association for the Study of Liver; CHB/C, chronic hepatitis B/C; HB/CV, hepatitis B/C virus; HCC, hepatocellular carcinoma; HOMA-IR, homeostasis model assessment-insulin resistance; NAFLD, non-alcoholic fatty liver disease; MetS, metabolic syndrome; NASH, non-alcoholic steatohepatitis; T2DM, type 2 diabetes mellitus.

* Corresponding author. Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, 7 Chung-Shan South Road, Taipei 10002, Taiwan.
E-mail address: kaojh@ntu.edu.tw (J.-H. Kao).

0929-6646/S - see front matter Copyright © 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
http://dx.doi.org/10.1016/j.jfma.2012.07.002
Introduction

Non-alcoholic fatty liver disease (NAFLD), which describes a condition of fat accumulation in the liver in the absence of excessive alcohol consumption and specific causes of hepatic steatosis, is the most common liver disorder in the world, affecting 20–40% of the general population in Western countries and 5–40% in the general population across the Asia-Pacific region. The prevalence of NAFLD, including the more aggressive non-alcoholic steatohepatitis (NASH), is increasing in parallel with the growing pandemics of obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome. A certain proportion of NASH patients progress to cirrhosis and its related complications, such as hepatocellular carcinoma (HCC). Previous studies showed that 10–29% of NASH patients may develop cirrhosis within 10 years, and 4–27% of these cirrhosis patients may have HCC (Fig. 1). Therefore, NAFLD/NASH will gradually become the major etiology of chronic liver disease worldwide.

Large population-based surveys in the Asia-Pacific region indicated that the prevalence rates of NAFLD range from 12% to 24% in population subgroups, depending on age, gender, ethnicity, and geographic location (urban vs. rural). In Taiwan, the prevalence of NAFLD is about 11.4–41% in two studies, and the rates are higher in population subgroups, from 66.4% in healthy taxi drivers to 80% in obese individuals who attended weight reduction programs. Although viral hepatitis continues to rage in Taiwan, the health impact of NAFLD has become increasingly recognized, and is likely to be a huge disease burden in the future. Therefore, it is time for us to formulate strategies in advance to cope with this growing health problem.

Diagnosis of NAFLD

Fatty liver or hepatic steatosis is characterized by triglyceride accumulation within the cytoplasm of hepatocytes, and includes a spectrum of liver disease from a benign simple steatosis, steatohepatitis, to fibrosis, and may progress to liver disease from a benign simple steatosis, steatohepatitis, to fibrosis, and may progress to liver cirrhosis, liver failure, and hepatocellular carcinoma. Several conditions have been linked to fatty liver. Among them, alcoholic liver disease and NAFLD are most common.

NAFLD is a more widely used term than "non-alcoholic steatohepatitis," which was originally developed by Ludvig in 1979 to describe an alcoholic-like liver disease in patients who do not drink alcohol on the basis of histological findings. Patients with NAFLD usually have slightly elevated liver enzyme values, deny excessive alcohol consumption, and have negative laboratory tests suggestive of viral hepatitis, autoimmune liver disease, and congenital causes of chronic hepatitis.

Although fatty liver may be identified by imaging modalities including ultrasonography, computed tomography (CT), and magnetic resonance imaging with a reasonably high sensitivity (~80% for 30% steatosis), steatohepatitis and fibrosis cannot be judged merely on image findings. Several new imaging modalities and biomarkers are emerging and may provide more detailed information about hepatic tissue or even replace biopsy, although most of them are not available on clinical practice, are expensive, need further validation, and remained research tools up to now. Accordingly, liver histology remains the gold standard for the diagnosis of NAFLD/NASH. Because it is often impractical to use a pathological definition in clinical practice and research studies, an operational definition of NAFLD has been proposed in the Asia-Pacific region.

According to the proposed Asian Pacific Association for the Study of Liver operational definition, fatty liver can be defined by the presence of at least two of three abnormal findings on abdominal ultrasonography: diffusely increased echogenicity ("bright") liver with liver echogenicity greater than kidney or spleen, vascular blurring, and deep attenuation of ultrasound signal. NAFLD is highly likely provided that the other causes of liver disease have been rigorously ruled out, particularly significant alcohol intake (more than 140 g weekly in men, 70 g weekly in women), hepatitis B, hepatitis C, and medication use. Alternatively, in patients with otherwise unexplained alanine aminotransferase (ALT) elevation, NAFLD is highly likely to be the cause if hepatic imaging results compatible with fatty liver, and metabolic risk factors are also present. However, in some clinical settings, liver biopsy is usually the first-line procedure for the diagnosis of NAFLD, such as in cases whose diagnosis are uncertain, who are at risk of advanced hepatic fibrosis (in the absence of clinical or imaging evidence of cirrhosis), or had both chronic liver diseases other than NAFLD and metabolic risk factors, or enrolled in clinical trials, or subjected to laparoscopy for another purpose (because of

![Figure 1](image-url)
reduced risk and greater convenience, e.g., cholecystec-
tomy, gastric banding,18 or during elective surgical
procedure (such as anti-obesity surgery).16 On the other
hand, liver biopsy should not be performed in patients with
recent weight change. A watchful period (4–6 months) is
useful, aimed at enforcing diet and lifestyle measures. If
these measures failed in weight loss, ALT normalization,
and a reduction of insulin resistance (IR), liver biopsy
should be considered after balancing the risk for advanced
fibrosis (age, diabetes, IR), patient motivation, and
competing comorbidities.16

Prevalence, clinical significance, and risk
factors of NAFLD worldwide

With the rising prevalence of obesity and T2DM worldwide,
NAFLD has become a major public health problem.19
Although NAFLD and NASH are now considered to be
common causes of chronic liver disease, an increasing
indication for liver transplantation and a possible cause of
HCC,12 it is difficult to determine the true prevalence of
NAFLD worldwide because of the problematic interpreta-
tion of data from various studies, such as referral bias,
population heterogeneity, study design, imaging modalities
used, and use of liver biopsies. On the basis of hepatic
imaging and/or quantification of hepatic triglyceride
content, the prevalence of fatty liver disease in Western
countries is estimated to be 24–42%, depending on gender
and ethnicity,12,13 and is higher in population subgroups,
such as 80% in obese individuals.20 Of particular note, about
3–15% of the general population has NASH.

Risk factors associated with the development of NAFLD
include older age, obesity, T2DM, as well as dyslipidemia.21
Therefore, NAFLD was conceptualized as a part of meta-
bolic syndrome (MetS).12,13,22,23 However, the association
of NAFLD with metabolic risk factors is only evident when
regional definitions of anthropometry are used.

NAFLD in the Asia-Pacific region

In the past, NAFLD has been thought to be uncommon in the
Asia-Pacific region because it was considered a disorder of
affluence, and in this region the burden of viral hepatitis is
huge.2,3 However, the major risk factors for NAFLD, like
glucose intolerance and T2DM, obesity, dyslipidemia, and
metabolic syndrome, are widely prevalent in the Asia-
Pacific region and increasing in geometric propor-
tions.19,24 Therefore, recent surveys by using ultrasonog-
raphy indicated that the prevalence of NAFLD in the
general population across Asia-Pacific region varies from 5% to
30%.20 In addition, a study from Japan demonstrated a 2.4-fold increasing prevalence of fatty liver over a 12-
year period,25 an implication that the prevalence is
indeed increasing in this region.

Prevalence and risk factors of NAFLD in Taiwan

Although some studies use laparoscopy or liver biopsy to
diagnose NAFLD in obese patients,26,27 the diagnostic
criteria for NAFLD among most epidemiologic studies in
Taiwan are based on the history without excessive alcohol
intake, chronic viral hepatitis, as well as known etiologies of
liver disease and ultrasonographic findings consistent with
fatty liver (Table 1).7–10,24,26,28,30–32,40,50,51 Several
studies on the general population and those undergoing
a health checkup showed the prevalence of NAFLD, ranging
from 11.4% to 41% in Taiwan.7,8 The prevalence is higher in
population subgroups, from 66.4% among 1635 volunteer
healthy taxi drivers (1541 males and 94 females)9 to 80% in
210 apparently healthy obese individuals who attended
weight reduction programs.10 In adolescents, the preva-
ience of NAFLD increased progressively from 16.0% in the
normal group to 50.5% in the overweight group, and 63.5%
among obese individuals.28

On the other hand, in a general population study that
included 11.4% (372/3260) individuals with elevated ALT,
NAFLD appears to be the most common cause of ALT
elevation and presumed liver injury in Taiwan, with a
prevalence of 33.6%, and followed by HBV (28.5%),
exunexplained cause (21.8%), HCV (13.2%), both HBV and HCV
(2.2%), and excess alcohol consumption (0.8%). In addition,
the prevalence of ALT elevation in NAFLD was 18.1% (125/
691) in adults20 and 23.3% (20/86) in adolescents.28

Risk factors associated with the presence of NAFLD in
Taiwan have been examined in the general population, obese
persons, or individuals who received laparoscopy, and male
gender, older age, BMI, obesity, waist circumference, dia-
betes, hypercholesterolemia, hypertriglyceridemia, hyper-
tension, elevated ALT, homeostasis model assessment-insulin
resistance (HOMA-IR), and hyperuricemia are the identified
risk factors.7,10,24,28,30,31 Of patients with metabolic disorders,
wast circumference and IR are independently associated
with fatty liver in obese individuals,10 and only hyper-
triglyceridemia was related to NAFLD in non-obese individ-
uals. In addition, presence of MetS, high blood pressure, and
high fasting glucose are independent factors related to an
increased risk of NASH.16

Therefore, the development of NAFLD in Taiwan is
closely associated with metabolic derangements, as
observed in other Asian countries. Metabolic disorders are
also related to ALT elevation in patients without known
etiologies of liver disease.

NAFLD and HCV in Taiwan

As hepatic steatosis is a well-known feature for patients
with HCV infection and may affect disease progression and
therapeutic response of antiviral therapy for Western
chronic hepatitis C (CHC) patients, it is thus important and
interesting to know the impact of hepatic steatosis on
Taiwanese CHC patients. To this end, Liu et al32 enrolled 95
naive Taiwanese patients infected with either hepatitis C
virus (HCV) genotype 1 (n = 57) or 2 (n = 38), receiving
interferon alone (n = 41) or in combination with ribavirin
(n = 54) therapy, and had available liver histological data.
In their study, about 44 (46%) patients had steatosis and
four (4%) patients had steatohepatitis. They demonstrated
the associations of steatosis and hyperglycemia (p = 0.01),
hypertriglyceridemia (p = 0.004), as well as body mass index
>27 (p = 0.009), while not with HCV genotype or viral load.
Of note, the grade of steatosis correlated well with the
<table>
<thead>
<tr>
<th>Key issue</th>
<th>Authors (year)</th>
<th>Case number</th>
<th>Diagnosis</th>
<th>What is known</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence and Risk factors</td>
<td>Hsiao et al (2004)</td>
<td>210</td>
<td>Ultrasonography plus elevation of serum ALT levels</td>
<td>The prevalence of NAFLD was 20.5% in obese patients. Both insulin resistance and ferritin elevation were significantly associated with NAFLD in obese patients.</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Lin et al (2005)</td>
<td>187 (33 with NAFLD)</td>
<td>Ultrasonography plus elevation of serum AST and ALT levels</td>
<td>The HFE mutations may not contribute to iron accumulation in CHC or NAFLD patients in Taiwan.</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Chen et al (2006)</td>
<td>3245</td>
<td>Ultrasonography and history</td>
<td>NAFLD is closely associated with elevated ALT, obesity, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, and hyperuricemia. Serum ALT level was not a good predictor in individuals with NAFLD.</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Huang et al (2007)</td>
<td>111</td>
<td>Laparoscopic bariatric surgery</td>
<td>MetS and NASH were common in severely obese Taiwanese adults. Presence of MetS, high blood pressure, and high fasting glucose increased the risk of NASH.</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>Fan et al (2008)</td>
<td>126</td>
<td>Laparoscopic bariatric surgery</td>
<td>Laparoscopic inspection of the abdominal cavity provides important and additional information for the final diagnosis of chronic liver diseases and detection of possible pathology in patients.</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Fu et al (2009)</td>
<td>220</td>
<td>Ultrasonography and testing negative for serum HBsAg and anti- HCV antibody</td>
<td>Obesity, ALT abnormality and elevated non-HDL-cholesterol are risk factors for NAFLD in adolescents. However, ALT alone is not a sufficient indicator; and ultrasonography of the liver should be part of the routine health examination of obese adolescents.</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Tung et al (2011)</td>
<td>1635</td>
<td>Ultrasonography</td>
<td>Gender-related differences of NAFLD. Hypertension, hyperuricemia, higher AST, higher ALT, hypertriglyceridemia, and higher fasting plasma glucose were significantly related to NAFLD in males but not related to NAFLD in females.</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Liu et al (2005)</td>
<td>95</td>
<td>Pathology</td>
<td>Risk factors of NAFLD include male gender, older age, BMI, obesity, waist circumference, diabetes, hypercholesterolemia, hypertriglyceridemia, hypertension, elevated ALT, homeostasis model assessment-insulin resistance (HOMA-IR) and hyperuricemia.</td>
<td>7,10,26,28,30,31</td>
</tr>
<tr>
<td>NAFLD and HCV</td>
<td></td>
<td></td>
<td></td>
<td>Hepatic steatosis in Taiwanese patients with CHC was associated with metabolic syndrome, but not with HCV genotype, advanced fibrosis or the response to antiviral therapy.</td>
<td>32</td>
</tr>
<tr>
<td>Pathophysiologic studies</td>
<td>Chu et al (2007)</td>
<td>144 (94 with NAFLD)</td>
<td>Ultrasonography</td>
<td>Modest correlations between plasma levels of TNF-alpha with ALT and triglyceride, and NAFLD patients with abnormal ALT had significantly higher plasma TNF-alpha levels than controls.</td>
<td>40</td>
</tr>
</tbody>
</table>
number of MetS parameters ($p = 0.018$), but not with lower sustained response rate. And the improvement of steatosis after treatment ($n = 19$) did not correlate with HCV genotype ($p = 0.850$) or sustained response to antiviral therapy ($p = 0.246$). Therefore, they concluded that hepatic steatosis in Taiwanese patients with CHC was associated with features of the metabolic syndrome, but did not correlate with HCV genotype, advanced fibrosis, or the response to antiviral therapy.

**Pathogenesis of NAFLD**

In the traditional "two hit" model of NASH pathogenesis, steatosis (the "first hit") will sensitize the liver to the "second hit," such as oxidative stress, cytokines, free fatty acids, as well as endoplasmic stress, and then leads liver to inflammation, fibrosis, and ultimately cirrhosis. However, because all of these "second hits" can contribute to both steatosis and progressive liver disease, current lines of evidence have implied that steatosis may be a part of the liver's early adaptive response to stress, rather than a prerequisite "hit," and the "second hit," oxidative stress, free fatty acids, endoplasmic stress, as well as cytokines are the true "hit." Therefore, in consideration of the mechanisms of cellular injuries and fibrosis in NAFLD patients, the "second hit" deserves much more attention. Accordingly, many hepatic and extrahaepatic mediators have been identified to play important roles in the development of inflammation and fibrosis of NASH/NAFLD patients. Some of them are produced directly as results of steatosis, hepatocyte injury, and apoptosis, such as IR, reactive oxygen species, and cytokines, or derived from Kupffer cell, T-cell, hepatic stellate cells, and other inflammatory cells; meanwhile, others are released indirectly as a response to hepatocyte injury or gut-derived bacterial products, including lipopolysaccharide and adipocytokines. Since all of them are potentially therapeutic targets for NAFLD, studies focusing on these mediators and mechanisms have increased dramatically and worldwide in recent decades.

**Pathophysiologic studies of NAFLD in Taiwan**

Several studies in Taiwan have also examined the pathophysiologic mechanisms of NAFLD. For example, Chu et al compared the differences of proinflammatory cytokines, IL-6, and IL-8, as well as disease severity between 94 NAFLD patients and 50 matched controls. They found that, compared with control group, NAFLD patients had significantly higher BMI ($p < 0.001$), fasting sugar ($p = 0.002$), cholesterol ($p = 0.017$), and triglyceride ($p < 0.001$) level. NAFLD patients with abnormal serum ALT had higher plasma IL-8 levels ($42.87 \pm 16.58$ pg/mL) than control groups ($9.19 \pm 1.75$ pg/mL, $p = 0.028$), but with comparable plasma IL-6 levels. In addition, the authors also evaluated the role of TNF-alpha in the pathogenesis of NAFLD and demonstrated differential plasma TNF-alpha levels between NAFLD and healthy individuals. They found that there were modest correlations between plasma levels of TNF-alpha with ALT ($r = 0.25$, $p < 0.005$) and triglyceride ($r = 0.40$, $p < 0.001$), and NAFLD patients with abnormal
ALT had significantly higher plasma TNF-alpha levels than controls (2.63 ± 0.44 vs. 1.56 ± 0.10 pg/mL, \( p = 0.016 \)).

On the other hand, Lin et al.\(^6\) examined HFE mutations and iron accumulation among 125 healthy individuals, 29 patients with CHC, and 33 patients with NAFLD in Taiwan. They found that all the enrolled participants were free from C282Y mutation, and the distributions of H63D mutation were comparable among healthy individuals, the CHC group, and the NAFLD group. Although 34.48% of CHC patients and 36.36% of NAFLD patients had increased serum iron store, there was no significant difference in the prevalence of HFE mutations between patients with increased serum iron store and those without in CHC or NAFLD group. Therefore, they concluded that HFE mutations may not contribute to iron accumulation in the CHC or NAFLD group even when serum iron overload is observed in more than one-third of these patients in Taiwan.\(^6\)

Recently, Hsiao et al.\(^42\) studied the beneficial effects of pioglitazone in NAFLD patients by using a high fat diet mice model and demonstrated the diminished oxidative damage of pioglitazone in “NAFLD” mice. They found that the high-fat diet induced hepatic steatosis may be improved by adding pioglitazone. Moreover, the increased oxidative stress and DNA damage, such as increased malondialdehyde concentration and 8-oxoG staining in the high-fat diet group, were attenuated by pioglitazone, and decreased gene expressions of antioxidant defense mechanism—Sod1, Sod2, Ogg1, and MutY in the high-fat diet group—were reversed by pioglitazone coadministration.\(^42\)

In addition, different kinds of animal models were used to explore the pathophysiologic mechanisms of NAFLD in Taiwan. For examples, Lin et al. studied the mechanisms that androgen/androgen receptor signaling regulates insulin sensitivity in hepatic androgen receptor-knockout mice.\(^43\) Yeh et al.\(^44\) examined the effects of high energy infusion and insulin treatment in diabetic rats. Chen et al.\(^45\) examined the effects of Metformin on gene expression and post-translational processing in laying hens. Amali et al.\(^46\) used TAA-treated zebrafish as a model of steatohepatitis, and Her et al.\(^46\) also used zebrafish to study the link between gankyrin, microRNAs, and liver steatosis. Interestingly, soft-shelled turtle was also used to examine the effect of dietary highly unsaturated fatty acids on lipid peroxidation of muscle and liver tissues in Taiwan.\(^48\)

**Assessment and management of NAFLD patients**

Because of the possibility of disease progression and a close link with metabolic syndrome, patients with NAFLD should be monitored for the changes in liver disease severity, components, and complications of the MetS.\(^15,18\) Therefore, several assays need to be used for the evaluation of liver function and complications of cirrhosis, such as ALT, platelet count, serum albumin, bilirubin, and prothrombin time. Abdominal ultrasonography may also be performed for the surveillance of HCC, particularly in patients with NASH-related cirrhosis (cryptogenic cirrhosis). Nevertheless, more studies are required to determine the benefit and cost-effectiveness of HCC surveillance in NAFLD patients. In addition, insulin resistance (HOMA-IR) score, which is calculated by serum glucose (mg/dL × 0.05551) × serum insulin (mU/L) divided by 22.5,\(^49\) and complications of MetS are required for screening and assessment, such as waist circumference (central obesity for Asian criteria), body height and weight (BMI), fasting blood glucose, serum lipids, blood pressure, and oral glucose tolerance test (if fasting blood glucose is ≥ 5.6 mmol/L, no history of diabetes).\(^15\)

The rationale for NAFLD/NASH treatment is to prevent or reverse hepatic injury induced by lipotoxicity.\(^16\) Although the best management strategy for NAFLD is yet to be defined, two strategies have been proposed at the 2009 European Association for the Study of the Liver meeting. The first strategy is to correct IR and hyperinsulinemia as well as reduce visceral adiposity, and the second is to prevent or reverse hepatic cellular injury.\(^16\) For the first strategy, weight loss, physical exercise, diet changes, reduction of sedentary lifestyle, insulin-sensitizing agents, and anti-obesity surgery are options, while lifestyle measures including diet control and increasing physical activity such as aerobic exercise are the first-line treatment and mainstay of management recommended by the Asia-Pacific Working Party on NAFLD.\(^18\) Accordingly, some weight reduction is usually required, and even limited physical activity more than none or any increase over baseline in physical exercise is preferable. Although the minimal amount of weight loss and physical activity has not been determined, targets supported by several International Societies for diabetes prevention could be applied in NAFLD/NASH patients. Ideally, the best regimen for NAFLD/NASH is a long-term, multidisciplinary, and personalized approach,\(^50\) while the most effective regimen and long-term adherence remain unclear and need future studies.\(^18\)

The role of pharmacotherapy remains investigational and is not recommended for clinical practice. Specific pharmacological treatment is not recommended for NAFLD patients, but identified metabolic risk factors, such as diabetes mellitus and dyslipidemia, should be treated and screened for regularly. For example, use of statins to treat hypercholesterolemia is safe and recommended. Obese patients who do not respond to attempted lifestyle measures should be referred to centers specializing in obesity management. In those refractory to medical measurements, consideration should be given to bariatric surgery or gastric ballooning.\(^15,18\) For specific liver-directed therapy to prevent or reverse hepatic cellular injury, as there is still no approved medication for NAFLD/NASH, all these liver-directed therapies should be considered experimental for now and need to be further examined especially for their long-term effects on histological endpoints and safety in the near future.

**Managements studies for NAFLD in Taiwan**

In Taiwan, two studies examined the effects of treatments on patients with ultrasound-diagnosed NAFLD.\(^51,52\) First, Wang et al.\(^51\) evaluated the safety and effectiveness of rosiglitazone in 68 inadequately controlled type 2 diabetes patients with NAFLD, and found that it was reasonably well tolerated and might improve one-third of patients’ liver function after treatment. In their study, only two (2.9%)
patients discontinued the treatment due to increase of aspartate aminotransferase (AST) or ALT levels to more than three times the upper limit of normal, and among the 60 patients who completed the study treatment, mean fasting plasma glucose, A1C, fasting plasma insulin, mean ALT, and HOMA-IR were all significantly reduced, whereas body weight was increased by a mean of 2.6 ± 2.4 kg ($p < 0.001$). In addition, 20 (33.3%) patients maintained their normal AST and ALT levels for at least three consecutive measurements and through the end of the study period. Second, Chen et al investigated the effects of varied therapeutic lifestyle programs on 54 patients with ultrasound-diagnosed NAFLD. They divided the participants into three groups—(1) diet plus exercise group ($n = 16$), (2) exercise group ($n = 23$), (3) control group ($n = 15$)—and found that both 10-week diet-plus-exercise and exercise-only therapeutic lifestyle programs are effective for improving anthropometric indices, insulin sensitivity, ultrasound findings, and physical fitness in NAFLD patients. However, only the diet-plus-exercise program resulted in significant improvement in liver biochemistry.52

## Perspectives

The prevalence of NAFLD in Taiwan is similar to other Asian countries. Along with the increasing trends in westernized lifestyle (including overnutrition, sedentary lifestyle), obesity, diabetes mellitus, as well as metabolic syndrome, a further increase in the clinical significance of NAFLD/NASH is anticipated. Of particular note is that NASH, albeit mild and slowly progressive, indeed exists in Taiwan.53 Therefore, after the control of chronic hepatitis B and C, NAFLD/NASH will become the most prominent liver disease and prophylactic measure, and active management strategies should be planned and implemented in time. Unfortunately, essential information regarding the active management of NAFLD remains deficient and more data are needed before the development of a practical and effective guideline. For example, clinical trials including active prophylactic measures and studies with long-term follow-up, especially on the durability of management, are needed. In addition, the diagnostic accuracy of all noninvasive measurements used to identify liver fibrosis seldom exceeds 75% to 80%.54 Furthermore, most of these measurements are not available in our daily clinical practice55,56 and may not substitute for liver biopsy in the management of NAFLD. Therefore, effective and practical measurements to assess the severity of NAFLD are still lacking. Finally, interaction between NAFLD and other liver diseases is a concern, especially in Taiwan where viral hepatitis is rampant. For example, diabetes and obesity have been linked to several important malignancies, including HCC, which is a well-known complication of chronic hepatitis in Taiwan.57 However, patients with chronic HCV infection are usually associated with a lower serum lipid profiles than healthy adults,58 and a clearance of HCV may increase the risk of cardiovascular diseases in some participants.59 Therefore, the situations are more complicated than ever, and not just a question of treat-or-not. Several issues remain unsolved and need further studies, such as the impact of NAFLD on disease progression of other liver diseases or therapy, interactions, and pathophysiological mechanisms.

## Acknowledgments

This work was supported by grants from the Buddhist Tzu Chi General Hospital, National Taiwan University Hospital, Liver Disease Prevention and Treatment Research Foundation, the Department of Heath, and the National Science Council, Executive Yuan, Taiwan. All authors declare the independence of researchers from funders.

## References


hepatitis in patients with non-alcoholic fatty liver disease. *BMC Gastroenterol* 2006;6:34.


